GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A, HCA2: hydroxy-carboxylic acid receptor 2
Molekulargewicht:
256.69
Reinheit:
99.39
CAS Nummer:
[862892-90-8]
Formel:
C10H13ClN4O2
Target-Kategorie:
GPR109A
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten